Rutgers University
Rutgers has been instrumental in getting the coronavirus vaccines to the public – most recently leading one of the largest phase 3 clinical trials sites in the world for the newly approved Johnson & Johnson vaccine, which is expected to play a pivotal role in stemming the pandemic.
Behind the university’s crucial efforts at New Jersey Medical School and Robert Wood Johnson Medical school is a Rutgers-led collaborative established two years ago to create clinical trial innovations that can speed the translation of research discoveries into improved patient care.
“Who could have imagined this would be needed so quickly?” said Barbara Tafuto, instructor in the health informatics department at the Rutgers University School of Health Professions and member of workforce development for the NJ Alliance for Clinical and Translational Science’s $29 million grant program known as NJACTS.
Lessons of COVID-19 research pivot in 2020 could improve medical studies
By (0)
Clinical research has been impacted by the COVID-19 pandemic, both positively and negatively, experts say. Photo by Cincinnati Children s Hospital
Dec. 28 (UPI) The COVID-19 pandemic has had both a positive and negative impact on medical research in 2020, delaying some trials while streamlining the process for others, according to experts.
The complexities of the pandemic, and quick shift in research focus toward better understanding of the coronavirus and finding a cure, put many studies looking into other diseases on hold for the short term.
Advertisement
Those delayed studies, many involving chronic, non-life-threatening diseases, were put on hold primarily because study participants were blocked from visiting research centers and a vast amount of medical resources were allocated